Who are the Institutional Holders in Zentalis Pharmaceuticals Inc (ZNTL)?

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) is -23.83% lower on its value in year-to-date trading and has touched a low of $9.56 and a high of $31.46 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ZNTL stock was last observed hovering at around $11.30 in the last trading session, with the day’s gains setting it 0.24%.

Currently trading at $11.54, the stock is -10.46% and -13.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.7 million and changing 2.12% at the moment leaves the stock -43.67% off its SMA200. ZNTL registered -45.64% loss for a year compared to 6-month loss of -54.89%. The firm has a 200-day simple moving average (SMA200) of -$1.51.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -29.55% gain in the last 1 month and extending the period to 3 months gives it a 13.14%, and is -1.28% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.11% over the week and 6.91% over the month.

Zentalis Pharmaceuticals Inc (ZNTL) has around 156 employees, a market worth around $816.69M and $0.00M in sales. Distance from 52-week low is 20.71% and -63.32% from its 52-week high. The company has generated returns on investments over the last 12 months (-54.52%).

Zentalis Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.92.The EPS is expected to shrink by -0.14% this year

198 institutions hold shares in Zentalis Pharmaceuticals Inc (ZNTL), with institutional investors hold 129.14% of the company’s shares. The shares outstanding are 70.77M, and float is at 63.53M with Short Float at 20.57%. Institutions hold 124.94% of the Float.

The top institutional shareholder in the company is Matrix Capital Management with over 13.96 million shares valued at $393.81 million. The investor’s holdings represent 19.73% of the ZNTL Shares outstanding. As of Jun 29, 2023, the second largest holder is FMR, LLC with 10.58 million shares valued at $298.37 million to account for 14.95% of the shares outstanding. The other top investors are Eventide Asset Management LLC which holds 6.88 million shares representing 9.72% and valued at over $194.02 million, while Vanguard Group Inc holds 6.97% of the shares totaling 4.93 million with a market value of $139.05 million.

Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity

A total of 9 insider transactions have happened at Zentalis Pharmaceuticals Inc (ZNTL) in the last six months, with sales accounting for 7 and purchases happening 2 times. The most recent transaction is an insider sale by Gallagher Cam, the company’s President. SEC filings show that Gallagher Cam sold 11,552 shares of the company’s common stock on Feb 02 at a price of $11.54 per share for a total of $0.13 million. Following the sale, the insider now owns 0.64 million shares.

Zentalis Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 02 that Epperly Melissa B, (Chief Financial Officer) sold a total of 8,669 shares of the company’s common stock. The trade occurred on Feb 02 and was made at $11.54 per share for $0.1 million. Following the transaction, the insider now directly holds 0.45 million shares of the ZNTL stock.

Still, SEC filings show that on Feb 02, Paul Andrea (Chief Legal Officer) disposed off 3,310 shares at an average price of $11.54 for $38197.0. The insider now directly holds 149,973 shares of Zentalis Pharmaceuticals Inc (ZNTL).

Zentalis Pharmaceuticals Inc (ZNTL): Who are the competitors?

One of the company’s main competitors (and peers) include Roche Holding AG Akt (RO) that is trading -28.04% down over the past 12 months.Rogers Corp. (ROG) lies in the list of competitors of the Zentalis Pharmaceuticals Inc and is -22.07% lower over the same period from ZNTLAstraZeneca PLC ADR (AZN) is -7.78% down on the 1-year trading charts.